81 reports

  • NIB-2

These post-hoc analysis results indicate that, in the subgroup with late onset asthma, reslizumab showed a ## percent reduction in asthma exacerbations and improvement in lung function as measured by forced expiratory volume in one second (FEV##).

  • Psychotic Disorder
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited

There are three types of vaccines: ##.

  • Hospital
  • Psychotic Disorder
  • AstraZeneca PLC
  • Lilly Endowment Inc.
  • Pfizer Inc.

Drivers and their Impact Impact on Key Customer Segments Driver Unmet Medical Needs Increase in Patient Population Low Low ## ## ## ## ## High High Hospitals ## ## ## ## ## Promising Drug Pipeline Special Provision for Rare Diseases Low Low ## ## ## ## ## High High ## ## ## ## ##

  • Psychotic Disorder
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.
  • DECREASE IN FEV1 IN PULMONARY SAFETY TRIALS OF ADASUVE

UA=##.

  • Psychotic Disorder
  • Alkermes plc
  • Janssen Biotech, Inc.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • 10. Market Growth Drivers

Currently, SCS systems are used for pain relief, but in the future they will be also used to treat angina and asthma.

  • Psychotic Disorder
  • Boston Scientific Corporation
  • Cyberonics, Inc.
  • Jude Medical, Inc.
  • Medtronic, Inc.

CVT-## WILL BE TAKEN AS NEEDED, SIMILAR TO A " RESCUE INHALER, " WHICH IS COMMON IN THE ASTHMA MARKET.

  • Psychotic Disorder
  • Forecast
  • Market Size
  • Merck & Co., Inc.
  • Novartis AG

Oct ##, 2016: Asthma research unexpectedly yields new treatment approach for inherited enzyme disease Experiments designed to reveal how a protein protects the lungs from asthma-related damage suggest a new way to treat a rare disease marked by the inability of cells to break down

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Genzyme Corporation

OCT ##, 2016: ASTHMA RESEARCH UNEXPECTEDLY YIELDS NEW TREATMENT APPROACH FOR INHERITED ENZYME DISEASE Experiments designed to reveal how a protein protects the lungs from asthma-related damage suggest a new way to treat a rare disease marked by the inability of cells to break down

  • Psychotic Disorder
  • Therapy
  • Brazil
  • Product Initiative
  • Protalix BioTherapeutics, Inc.

IT AFFECTS ## IN ##, ## TO ## IN ##, ## BIRTHS.

  • Clinical Trial
  • Hospital
  • Nucleic Acid
  • Psychotic Disorder
  • GlobalData's company

Termination of partnership agreements with either one or few major distributors may affect the business operations.

  • Psychotic Disorder
  • United Kingdom
  • United States
  • Company
  • Britannia Pharmaceuticals Ltd.
  • DORMANT PRODUCTS, H2 2018 (CONTD..2), H2 2018

Patients will be randomized to receive one of two doses of BNC## (##mg or 2000mg) or one of two controls, placebo or ##. ##mg Lorazepam.

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Bionomics

It is also developing new approaches to the treatment of asthma.

  • Psychotic Disorder
  • Therapy
  • United States
  • World
  • Product Initiative

It is also developing new approaches to the treatment of asthma.

  • Biotechnology
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • Belgium

In July, the company to divest the U. S. market rights to Asthma and Allergy Products to Covis Pharma Sarl.

  • Psychotic Disorder
  • United States
  • Company
  • Litigation And Patent
  • Sunovion Pharmaceuticals Inc.

NO has a solid place in asthma management.

  • Drug Test
  • United States
  • Alere Inc.
  • Dräger Group
  • Thermo Fisher Scientific, Inc.

Each Unit consists of one common share and one share purchase warrant.

  • Psychotic Disorder
  • Canada
  • United States
  • Corporate Finance
  • Sunovion Pharmaceuticals Inc.
  • Pipeline by Merck & Co Inc, H1 2018

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Hospital
  • Pharmaceutical
  • Psychotic Disorder
  • World
  • Product Initiative
  • Pipeline by OPKO Health Inc, H1 2017

Small molecules are jun-N-terminal kinases (JNK) (JNK-##, ##, ##) inhibitor.

  • Hormone
  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • Pipeline by Merck & Co Inc, H2 2017

Researchers identified ##-[##-fluoro-##-(##H-pyrazol-##-yl)phenyl]-##-methoxy-##-(##-phenyl-##H-pyrazol-##yl)pyridazin-##(##H)-one (##h).

  • Pharmaceutical
  • Psychotic Disorder
  • Turkey
  • World
  • Product Initiative

Presented preclinical data for PRX## at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2016 Annual Meeting demonstrating the ability of PRX## to inhibit migration of disease-causing T cells.

  • Psychotic Disorder
  • United States
  • World
  • Company Financials
  • Prothena Corporation plc
  • DORMANT PRODUCTS, H1 2018 (CONTD..2), H1 2018

Patients will be randomized to receive one of two doses of BNC## (##mg or 2000mg) or one of two controls, placebo or ##. ##mg Lorazepam.

  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Bionomics
  • PIPELINE BY DENOVO BIOPHARMA LLC, H2 2018
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development

It is also developing new approaches to the treatment of asthma.

  • Psychotic Disorder
  • Therapy
  • United States
  • World
  • Product Initiative

Dr Glimcher is a member of the Blue Ribbon Panel Advisory Board of the National Cancer Institute and of the American Asthma Foundation.

  • Clinical Trial
  • Psychotic Disorder
  • United States
  • Company
  • Aequus Pharmaceuticals Inc.

It is also developing new approaches to the treatment of asthma.

  • Psychotic Disorder
  • Therapy
  • World
  • Product Initiative
  • Addex Therapeutics Ltd

THE COMPANY CURRENTLY HAS CLINICAL TRIALS UNDERWAY FOR ASTHMA, AUTISM, MULTIPLE SCLEROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, AND SCIS.

  • Psychotic Disorder
  • North America
  • United States
  • Athersys, Inc.
  • Vericel Corporation

Lignamed (spinout from University of Pennsylvania) is developing LGM-## for the protection of normal healthy lung tissue from radiation damage, idiopathic pulmonary fibrosis pneumonitis and asthma.

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative
  • RPI

The subscribers of the convertible notes will for each convertible note also receive one warrant entitling the holder to subscribe for one new or treasury share in the company.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company Financials
  • Acorda Therapeutics, Inc.
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Indication, 2016

DSP-## (AZD-##) was under development for the treatment of bronchial asthma, allergic asthma, and allergic rhinitis.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Sumitomo Dainippon Pharma Co., Ltd.

It is also developing new approaches to the treatment of asthma.

  • Psychotic Disorder
  • United Kingdom
  • United States
  • Company
  • Heptares Therapeutics Limited